Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Kimble

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
European Journal of Pharmacology|January 20, 1987
CGS 15435A, a thromboxane synthetase inhibitor with an extended duration of action: a comparison with dazoxibenR W Olson, D S Cohen, E C Ku, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 17, 2006
Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitorsTsung H Lin, Axel Metzger, David J Diller, et al.
Journal of Medicinal Chemistry|November 12, 1993
Substituted chromenes as potent, orally active 5-lipoxygenase inhibitorsY Satoh, J L Stanton, A J Hutchison, et al.
Arzneimittel-Forschung|September 1, 1992
Hypolipidaemic activity of a novel acyclic ansamycin derivative. Synthesis and pharmacokinetic and pharmacodynamic studies in rodentsK A Menear, K E Dunnet, J G Hastewell, et al.
Biochimica Et Biophysica Acta|April 15, 1988
Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo modelsE C Ku, A Raychaudhuri, G Ghai, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 1, 1997
Inhibition of LTB4 biosynthesis in situ by CGS 23885, a potent 5-lipoxygenase inhibitor, correlates with its pleural fluid concentrations in an experimentally induced rat pleurisy modelA Raychaudhuri, H Chertock, J Chovan, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1989
Characterization of CGS 8515 as a selective 5-lipoxygenase (5-LO) inhibitorE C Ku, A Raychaudhuri, G Ghai, et al.
Journal of Veterinary Pharmacology and Therapeutics|January 24, 2009
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2J N King, J Dawson, R E Esser, et al.
Bioorganic & Medicinal Chemistry Letters|September 28, 2010
Discovery of 2-aminoimidazopyridine adenosine A(2A) receptor antagonistsBrian F McGuinness, Andrew G Cole, Guizhen Dong, et al.
British Journal of Pharmacology|January 19, 2005
Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2Ronald Esser, Carol Berry, Zhengming Du, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
European Journal of Pharmacology|January 20, 1987
CGS 15435A, a thromboxane synthetase inhibitor with an extended duration of action: a comparison with dazoxibenR W Olson, D S Cohen, E C Ku, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 17, 2006
Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitorsTsung H Lin, Axel Metzger, David J Diller, et al.
Journal of Medicinal Chemistry|November 12, 1993
Substituted chromenes as potent, orally active 5-lipoxygenase inhibitorsY Satoh, J L Stanton, A J Hutchison, et al.
Arzneimittel-Forschung|September 1, 1992
Hypolipidaemic activity of a novel acyclic ansamycin derivative. Synthesis and pharmacokinetic and pharmacodynamic studies in rodentsK A Menear, K E Dunnet, J G Hastewell, et al.
Biochimica Et Biophysica Acta|April 15, 1988
Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo modelsE C Ku, A Raychaudhuri, G Ghai, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 1, 1997
Inhibition of LTB4 biosynthesis in situ by CGS 23885, a potent 5-lipoxygenase inhibitor, correlates with its pleural fluid concentrations in an experimentally induced rat pleurisy modelA Raychaudhuri, H Chertock, J Chovan, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1989
Characterization of CGS 8515 as a selective 5-lipoxygenase (5-LO) inhibitorE C Ku, A Raychaudhuri, G Ghai, et al.
Journal of Veterinary Pharmacology and Therapeutics|January 24, 2009
Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2J N King, J Dawson, R E Esser, et al.
Bioorganic & Medicinal Chemistry Letters|September 28, 2010
Discovery of 2-aminoimidazopyridine adenosine A(2A) receptor antagonistsBrian F McGuinness, Andrew G Cole, Guizhen Dong, et al.
British Journal of Pharmacology|January 19, 2005
Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2Ronald Esser, Carol Berry, Zhengming Du, et al.
Pageof 3